

THE INTERNATIONAL JOURNAL OF SCIENCE & TECHNOLEDGE

Synthesis and Characterization of Some Isoxazole Derivatives of Vanillin as Antimicrobial Agent

J. V. Dodia

Department of Chemistry, Kamani Science College, Amreli, Gujarat, India

V. R. Dangar

Department of Chemistry, Kamani Science College, Amreli, Gujarat, India

V. R. Shah

Department of Chemistry, Kamani Science College, Amreli, Gujarat, India

Abstract:

Some new 5-(*p*-Methoxyphenyl)-3-[3'-methoxy-4'-(*p*-methylbenzyloxy)phenyl]-isoxazole were prepared. All the prepared compounds were characterized by their spectral (I.R., N.M.R., Mass) data and screened for their antimicrobial activities.

Key words: Chalcone, Isoxazole, Antimicrobial activities

1. Introduction

The chemistry of chalcones has generated interest in scientific studies throughout the world, especially for their biological and industrial applications. Kostanecki and Tambor¹ gave the name chalcone. Different methods are available for the synthesis of chalcones. The most convenient method is the one that involves the Claisen-Schmidt condensation of equimolar quantities of aryl methyl ketones with aryl aldehyde in the presence of alcoholic alkali^{2,4}. Chalcone derivatives have been found to possess wide range of therapeutic activities such as Antitumor⁵, Antispasmodic⁶, Antiulcer⁷, Anthelmintics⁸, Bactericidal⁹, Cardiovascular¹⁰, Fungicidal¹¹, Germicidal¹², Herbicidal¹³, Insecticidal¹⁴, Antiviral¹⁵.

In 1888 Claisen first suggested the synthesis for isoxazole from the reaction of 1,3 diketone with hydroxyl amine¹⁶ subsequently a solid foundation for the chemistry of isoxazoles was laid down by Claisen and his students. It was shown to possess typical properties of an aromatic system by under certain reaction conditions. Particularly in reducing or basic media it becomes very highly labile. Isoxazole derivatives exhibit various biological activities such as, Antipyretic¹⁷, Anticonvulsant¹⁸, Anticholestermic¹⁹, Anticancer²⁰, Anthelmintics²¹, Antiinflammatory²², Adenosine antagonist²³, Fungicidal²⁴, Herbicidal²⁵, Hypoglycemic²⁶, Musclerelaxant²⁷, Nematocidal²⁸, Insecticidal²⁹, Antiviral³⁰, Antimicrobial³¹.

The structure of synthesized compounds were assigned based on Elemental analysis, I.R. ¹H-NMR and Mass spectral data. The antimicrobial activity was assayed by using the cup-plate agar diffusion method³² by measuring the zone of inhibition in mm. All the compounds were screened *in vitro* for their antimicrobial activities³³ against varieties of bacterial strains such as *Staphylococcus subtilis*, *Escherichia coli*, *Proteus vulgaris* and fungi *Aspergillus niger* at 40 µg concentration. Standard drugs like Ampicillin, Amoxicillin, Norfloxacin, Benzyl penicillin and Griseofulvin were used for comparison purpose (Table-2).

2. Experimental Section

Melting points were taken in open capillary and are uncorrected. IR spectra (cm⁻¹) were recorded on Shimadzu-435-IR Spectrophotometer and ¹H-NMR spectra on Bruker spectrometer (300MHz) using TMS as an internal standard, chemical shift is in δ ppm.

2.1. Preparation of 3-Methoxy-4-(*p*-methylbenzyloxy)-benzaldehyde :

The solution of Vanillin (1.53g, 0.01M) in DMF (7.7ml) was heated at 50-55°C in presence of 4-methylbenzyl chloride (1.75g, 0.01) and K₂CO₃ (2.76gm, 0.02) for 5 hrs, after 5 hrs product was precipitated by adding the solution in to cold water. The separated solid was filtered and crystallized from ethanol. Yield 90%, m.p.84°C.

2.2. 3-Methoxy-4-(*p*-methylbenzyloxy)-benzaldehyde: (A)

Yield 90%, m.p. 84 °C; IR(KBr) : ν 3032(C-H Str.), 1273 (-OCH₃), 1226 (Ar-O-C) cm⁻¹, ¹H-NMR (CDCl₃) : δ 9.83 (s,1H,-CHO), 5.21 (s,2H,-O-CH₂-) 6.96-7.41 (m,7H, Ar-H) 3.94 (s,3H,-OCH₃) 2.95 (s,3H,-CH₃). Mass m/z 256 M.F.:C₁₆H₁₆O₃. M/z: 112,134,161,213,226,255.

2.3. Preparation of 1-Aryl-3-[4'-(p-methylbenzyloxy)-3'-methoxyphenyl]-propenones (1b) :

A mixture of 3-Methoxy-4-(p-methylbenzyloxy)-benzaldehyde (A) (0.01M) and 4-methoxy acetophenone (0.01) was taken in methanol, NaOH (0.002M) was added to the reaction mixture. The reaction mixture was then magnetically stirred for 12 hrs and left overnight. It was poured over crushed ice and neutralized with dilute HCl. It was crystallized from ethanol. Similarly, other chalcones were prepared and its physical data are recorded in Table no. 1

2.4. 1-(p-Methoxyphenyl)-3-[4'-(4-methylbenzyloxy)-3'-methoxyphenyl]-propenones (1b):

Yield 76%, m.p. 112^oC; IR(KBr) : ν 2968, 2841, 1456 (Alkane, -CH₃), 1255 (-OCH₃), 1255 (Ar-O-C), 1653 (C=O), 1591 (C=C), C=C Str. 1512, C-H i. p. (def.) 1133, C-H o.o.p. (def.) 817 cm⁻¹; ¹H-NMR (CDCl₃) : δ 2.26 (s, 3H, -CH₃), 3.84 & 3.86 (s, 6H, -OCH₃), 7.33 & 7.67 (d, 2H, -CH=CH-), 5.09 (s, 2H, -O-CH₂-), 6.80-7.96 (m, 11H, Ar-H). Mass m/z 388. M.F.: C₂₅H₂₄O₄. m/z: 43, 77, 92, 105, 135, 176, 284, 388.

2.5. Preparation of 3-(p-Methoxyphenyl)-5-[3'-methoxy-4'-(p-methylbenzyloxy)phenyl]-isoxazole (2b) :

A mixture of Hydroxylamine hydrochloride (0.01M), 1-Aryl-3-[4'-(p-methylbenzyloxy)-3'-methoxyphenyl]-propenones (1a-l) (0.01M) and CH₃COONa (0.01M) in ethanol was refluxed with stirring for about 6-8 hrs until the reaction was complete, which was monitored as formation of precipitate of isoxazole took place. Similarly, other isoxazoles were prepared and its physical data are recorded in Table no. 1

2.6. 3-(p-Methoxyphenyl)-5-[3'-methoxy-4'-(p-methylbenzyloxy)phenyl]-isoxazole :

Yield 68%, m.p. 121^oC; IR(KBr) : ν 2938, 3049, 1466 (Alkane, -CH₃), 1252 (-OCH₃); 1030 (Ar-O-C), 1605 (C=N), 833 (N-O), 1595, 1112, 833 (Aromatic); ¹H-NMR (CDCl₃) : δ 2.35 (s, 3H, -CH₃), 3.86, (s, 6H, -OCH₃), 5.09 (s, 2H, -O-CH₂-), 6.80-7.96 (m, 12H, Ar-H). Mass m/z 401. M.F.: C₂₅H₂₃O₄N. m/z : 41, 51, 77, 92, 105, 135, 147, 210, 296, 388, 401.

3. Results and Discussion

The synthesis of 1-Aryl-3-[4'-(p-methylbenzyloxy)-3'-methoxy-phenyl]-propenones (1a-l) and 3-Aryl-5-[3'-methoxy-4'-(p-methylbenzyloxy)phenyl]-isoxazole (2a-l) was carried out in two steps, first by the condensation of 3-Methoxy-4-(p-methylbenzyloxy)-benzaldehyde (A) with different aromatic acetophenones by Claisen-Schmidt condensation in presence of basic catalyst to give chalcone derivatives (1a-l), which in next step were refluxed with hydroxyl amine hydrochloride and sodium acetate to yield isoxazole derivatives (2a-l). (scheme-1).

The formulas of the selected compounds were confirmed by the elemental analysis and their structures were determined by IR, ¹H-NMR and mass spectral data.

Characterization data of the compounds (1a-l) and (2a-l)						
Compd. no.	R	Molecular Formula	Mole. Wt.	M.P. (°C)	Nitrogen %	
					Calcd.	Found
1a	-C ₆ H ₅	C ₂₄ H ₂₂ O ₃	358.0	122	-	-
1b	-4-NH ₂ -C ₆ H ₄	C ₂₄ H ₂₃ NO ₃	373.0	170	3.75	3.71
1c	-4-Br-C ₆ H ₄	C ₂₄ H ₂₁ O ₃ Br	437.0	112	-	-
1d	-4-Cl-C ₆ H ₄	C ₂₄ H ₂₁ ClO ₃	392.5	108	-	-
1e	-2,4-(Cl) ₂ -C ₆ H ₃	C ₂₄ H ₂₀ Cl ₂ O ₃	427.0	140	-	-
1f	-2-OH-C ₆ H ₄	C ₂₄ H ₂₂ O ₄	374.0	73	-	-
1g	-3-OH-C ₆ H ₄	C ₂₄ H ₂₂ O ₄	374.0	78	-	-
1h	-4-OH-C ₆ H ₄	C ₂₄ H ₂₂ O ₄	374.0	72	-	-
1i	-4-OCH ₃ -C ₆ H ₄	C ₂₅ H ₂₄ O ₄	388.0	112	-	-
1j	-4-CH ₃ -C ₆ H ₄	C ₂₅ H ₂₄ O ₃	372.0	134	-	-
1k	-3-NO ₂ -C ₆ H ₄	C ₂₄ H ₂₁ O ₅ N	403.0	92	3.47	3.46
1l	-4-NO ₂ -C ₆ H ₄	C ₂₄ H ₂₁ O ₅ N	403.0	148	3.47	3.45
2a	-C ₆ H ₅	C ₂₄ H ₂₁ O ₃ N	371	102	3.77	3.73
2b	-4-NH ₂ -C ₆ H ₄	C ₂₄ H ₂₂ O ₃ N ₂	386	145	7.25	7.22
2c	-4-Br-C ₆ H ₄	C ₂₄ H ₂₀ O ₃ NBr	450	125	3.11	3.10
2d	-4-Cl-C ₆ H ₄	C ₂₄ H ₂₀ O ₃ NCl	405	85	3.45	3.40
2e	-2,4-(Cl) ₂ -C ₆ H ₃	C ₂₄ H ₁₉ O ₃ NCl ₂	440	92	3.18	3.16
2f	-2-OH-C ₆ H ₄	C ₂₄ H ₂₁ O ₄ N	387	90	3.61	3.60
2g	-3-OH-C ₆ H ₄	C ₂₄ H ₂₁ O ₄ N	387	116	3.61	3.59

2h	-4-OH-C ₆ H ₄	C ₂₄ H ₂₁ O ₄ N	387	101	3.61	3.58
2i	-4-OCH ₃ -C ₆ H ₄	C ₂₅ H ₂₃ NO ₄	401	121	3.49	3.48
2j	-4-CH ₃ -C ₆ H ₄	C ₂₅ H ₂₃ NO ₃	385	114	3.63	3.61
2k	-3-NO ₂ -C ₆ H ₄	C ₂₄ H ₂₀ N ₂ O ₅	416	78	6.73	6.70
2l	-4-NO ₂ -C ₆ H ₄	C ₂₄ H ₂₀ N ₂ O ₅	416	90	6.73	6.71

Table 1

3.1. Antibacterial Activity

It has been observed from the microbiological data that all compounds (1a-l) and (2a-l) were found to be mild to moderately active against Gram positive and Gram negative bacterial strains. However the maximum activity was observed in compounds (1c), (1h), (2a), (2l) against *S. aureus*. The significant activity was observed in compounds (1h), (1j), (2j), (2l) against *B. subtilis*. The maximum activity was displayed by the compounds (1e), (1i), (2b), (2g) against *E. coli*. The compounds (1b), (1i), (2h), and (2i) were comparatively more effective against *P. vulgaris*.


3.2. Antifungal Activity

The antifungal data revealed that compounds were least toxic to the fungal strain. However mild activity was shown by the compounds (1e), (1h), (1l), (2b), (2e), (2f) against *A. niger*.

The antibacterial activity was compared with standard drug viz. Ampicillin, Amoxicillin, Norfloxacin, Benzyl penicillin and antifungal activity was compared with standard drug Griseofulvin.

Compd no.	Antibacterial activity (zone of inhibition in mm)				Antifungal Activity
	<i>S. aureus</i>	<i>B. subtilis</i>	<i>E. coli</i>	<i>P. vulgaris</i>	<i>A. niger</i>
1a	10	17	17	15	16
1b	18	14	15	18	15
1c	20	15	15	16	14
1d	16	17	18	13	13
1e	14	10	19	18	20
1f	15	12	13	17	15
1g	18	16	16	15	17
1h	19	18	15	16	18
1i	12	16	19	19	18
1j	13	19	16	15	16
1k	18	15	15	14	17
1l	12	17	17	11	19
2a	21	21	22	16	13
2b	17	20	24	22	22
2c	15	15	21	23	20
2d	20	13	19	21	18
2e	15	23	20	19	22
2f	16	17	18	18	23
2g	19	14	23	22	19
2h	15	18	16	24	17
2i	12	15	14	23	20
2j	18	22	16	17	21
2k	20	18	19	20	16
2l	21	22	20	19	17
Ampicillin	22	20	21	24	0
Amoxicillin	20	23	22	21	0
Norfloxacin	19	20	23	22	0
Benzyl penicillin	21	21	19	18	0
Griseofulvin	0	0	0	0	25

Table 2



Scheme 1

4. Conclusion

The present study leads to a convenient synthetic method for the synthesis of new compounds. Which showed significant antibacterial and antifungal activity. Further investigation with appropriate structural modification of the above compounds may result in therapeutically useful products.

5. Acknowledgement

The authors are thankful to authorities of Kamani Science College, Amreli for providing research facilities and also thankful to Department of Chemistry, Saurashtra University, Rajkot for I.R., N.M.R., Mass spectral & elemental analysis.

6. References

1. S. V. Kostanecki and J. Tambor; Chem. Ber., 32, 1921 (1899).
2. B. S. Holla and S. Y. Ambekar; J. Indian Chem. Soc., 50, 673 (1973); Chem. Abstr., 80, 132961 (1974).
3. K. Kazauki, K. Htayama, S. Yokomor and T. Soki; Japan Kokai 75, 140, 429, (Cl. C07 C A61K) 11 Nov. 1975, Appl. 74, 44, 152, 19 Apr. 1974; 4, p.p.; Chem. Abstr., 85, 5913 (1976).
4. H. Rupe and D. Wasserzug; Chem. Ber., 34, 3527 (1901).
5. Kamei, Hideo, Koide, Tatsurou; Hashimoto Yoko, Kojima et al.; Cancer Biother Radio Pharm. 1997, 12(1), 51-54 (Eng.); Chem. Abstr., 126, 258666v (1997).
6. A. C. Grosscort, H. R. Van and K. Wellinga; J. Agric. Food Chem., 27(2), 406 (1979); Chem. Abstr., 91, 15123x (1979).
7. Tashio Pharmaceutical Co Ltd.; Japan, Kokai Tokkyo Koho Jp. 51, 12, 094 (Cl A 61 K 31/215); Chem. Abstr., 101, 54722j (1984).
8. M. R. Bell; US Appl. 637, 931 (1984); Chem. Abstr., 113, 211828t (1990).
9. Y. Inamori et al.; Chem. Pharm. Bull., 39(6), 1604 (1991); Chem. Abstr., 115, 105547c (1991).
10. E. Marmo, A. P. Caputi and S. Cataldi; Farmaco Ed. Prat. 28(3), 132 (1973); Chem. Abstr., 79, 13501v (1973).
11. V. M. Gaurav and D. B. Ingle; Indian J. Chem. 25B(8), 868 (1986); Chem. Abstr., 103, 17, 39321h (1987).
12. S. S. Mishra and S. C. Kushwaha; J. Indian Chem. Soc., 64, 640 (1977)..
13. Parmar Virinder S; Jain Subhash C; et al.; Indian J. Chem., Sect. B., Org. Chem. Incl Med. Chem. 1998. 37B(7), 628-643 ng.), CSIR, Chem. Abstr., 129, 289910m (1998).
14. S. R. Modi and H. B. Naik; Orient J. Chem., 10(1), 85-6 (1994); Chem. Abstr., 122, 81186c (1995).
15. D. Binder, C. R. Noe, W. Holzer and B. Rosenwirth; Arch. Pharm. 318(1), 48 (1985); Chem. Abstr., 102, 149025u (1985).
16. L. Claisen and O. Lowmann; Chem. Ber., 21, 1149(1988).
17. B. Victor J. Safir and Sidney R. (American Cyanamid Co.) Brit. 1, 178064 (Cl C07D) (1970); Chem. Abstr., 72, 79017d (1970).
18. T. Tochiro, K. Shrji, I. Shinji, M. Hiroshi, S. Akira, V. Hiroshi; Gen. Offen. DE, 3, 237,149 (Cl. CO7A 261114) (1983); Chem. Abstr., 99, 88188 (1984).
19. R. Major, B. Eisele, P. Mutler and H. Grube; Ger. Offen. DE, 3621372 (1988); Chem. Abstr., 108, 67456r (1988).
20. Li W. T., Hwang D. R., Chen C. P., Shen C. W., Huang C. L., Chen T. W., Lin C. H., Chen S. J., Wu S. H., Chen C. T.; J. Med. Chem., 46, 1706 (2003).
21. S. Rung and D. Dus; Pharmazie, 49, 727 (1994); Chem. Abstr., 122, 55934h (1995).
22. Vamanauchi Pharm. Co. Ltd.; Jpn Kokai Koho JP, 58, 148, 858 (Cl. CO7D 207/333) (1982); Chem. Abstr., 100, 34538 (1984).
23. I. A. Shehata and R. A. Glannoh; J. Heterocycl. Chem., 24, 1291 (1987).
24. M. D. Mackie, H. S. Anthony, W. J. R. Howe, S. P. John and W. S. Marry; Brit.; UK Pat. Appl. GB 2, 265, 371 (Cl. C07 D 261/06); Chem. Abstr., 120, 164153z (1994).
25. A. K. Banerjee; Arzneim Forsch., 44, 863 (1994); Chem. Abstr., 122, 160522n (1995).
26. Inai Masatoshi, Tanaka Akie, Goto Kyoto; Jpn Kokai Tokkyo Koho JP, 07, 215, 952 (95, 215, 952) (1995); Chem. Abstr., 124, 86995s (1996).
27. Nippon Chemiphar Co. Ltd.; Jpn. Kokai Koho JP, 58, 46,077 (Cl. CO7A 261/14) (1983); Chem. Abstr., 99, 17574 (1984).

28. D. J. David, D. B. Allon and E. A. Frederick; Ger. Offen., 2, 723,688 (Cl. A01N 9/28) (1977); Chem. Abstr., 88, 132015k (1978)
29. Sezer Ozkan, Debak Kudir, Anac Okay, Akar Ahmet; Heterocycl. Commun., (1999); Chem. Abstr., 131, 5221f (1999).
30. C. P. Alfred, C. David Herman, D. Nancy, B. Daniel; PCT Int. Appl. WO, 95, 22, 9103 (1995); Chem. Abstr., 124, 3055m (1996).
31. Tomita K., Takahi Y. and Vdaira H; Ann. Sankyo Res. Lab., 1, 25 (1973).
32. A. L. Barry; The antimicrobial susceptibility test: Principle and practices, edited by Illuslea & Febiger , (Philadelphia), USA, 180; Biol. Abstr., 1977, 64, 25183
33. Panda J. Srinivas S. V., Rao M. E.;J. Indian Chem. Soc., 79(9), 770-1 (2002); Chem. Abstr., 138, 153499n (2003)